Viatris Inc. has been fined 7.58 million Moroccan dirhams, equivalent to approximately $760,000, by Morocco's competition regulator. The penalty was imposed for the company's failure to notify the regulator regarding its merger, which formed Viatris in 2020 from Mylan and Pfizer's Upjohn business.
The fine amount represents 2.5% of Viatris's revenue in Morocco during the previous year. Company sources confirmed that the fine has already been paid to the Moroccan treasury, resolving this specific compliance issue.
This regulatory action underscores the importance of adhering to local competition laws and notification requirements in all markets where Viatris operates. It highlights the ongoing challenges and potential financial implications associated with managing a global pharmaceutical enterprise across diverse regulatory landscapes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.